Literature DB >> 29314338

Reduced CDHR3 expression in children wheezing with rhinovirus.

Katarina Stenberg Hammar1,2,3, Katarzyna Niespodziana4, Marianne van Hage5, Juha Kere6,7, Rudolf Valenta4, Gunilla Hedlin1,2,3, Cilla Söderhäll1,3,6.   

Abstract

BACKGROUND: Rhinovirus-induced wheezing in young children has been associated with increased asthma risk at school age. Recently, the transmembrane protein cadherin-related family member 3 (CDHR3) was identified as the RV-C receptor and the genetic variant rs6967330 (p.Cys529Tyr) was reported to be associated with enhanced RV-C binding and increased replication in vitro. The aim of this study was to examine rs6967330 genotypes and mRNA expression of CDHR3 in relation to presence of rhinovirus and clinical symptoms in children with acute wheezing and compare to a group of age-matched healthy children.
METHODS: rs6967330;G>A was genotyped (n = 216), and CDHR3 mRNA expression was measured in peripheral blood leukocytes (n = 69) from a subgroup of children wheezing with RV infection acute and at a follow-up visit 2-3 months later, and in healthy controls. Standardized TaqMan assays were used.
RESULTS: The risk allele rs6967330-A was over-represented in the wheezing group (P < .001). Reduced mRNA levels of CDHR3 were found in children with acute wheezing as compared to the control group (P = .001). Children with the rs6967330 genotypes AA/AG showed the largest differences in CDHR3 expression between acute and follow-up visit (P < .04).
CONCLUSIONS: Preschool children with RV-induced wheezing were shown to have reduced CDHR3 mRNA levels, which might result in an increased permeability of the epithelial layers of the airways and thereby an increased vulnerability. Thus, measuring CDHR3 mRNA levels might help to identify a more severe phenotype of wheezing preschool children.
© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  acute wheezing; cadherin-related family member 3; mRNA expression; peripheral blood leukocytes; rhinovirus; rs6967330

Mesh:

Substances:

Year:  2018        PMID: 29314338     DOI: 10.1111/pai.12858

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  6 in total

1.  Functional genomics of CDHR3 confirms its role in HRV-C infection and childhood asthma exacerbations.

Authors:  Jamie L Everman; Satria Sajuthi; Benjamin Saef; Cydney Rios; Ari M Stoner; Mari Numata; Donglei Hu; Celeste Eng; Sam Oh; Jose Rodriguez-Santana; Eszter K Vladar; Dennis R Voelker; Esteban G Burchard; Max A Seibold
Journal:  J Allergy Clin Immunol       Date:  2019-03-29       Impact factor: 10.793

2.  Genetic susceptibility to severe childhood asthma and rhinovirus-C maintained by balancing selection in humans for 150 000 years.

Authors:  Mary B O'Neill; Guillaume Laval; João C Teixeira; Ann C Palmenberg; Caitlin S Pepperell
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

Review 3.  Rhinovirus and Asthma Exacerbations.

Authors:  Joshua L Kennedy; Sarah Pham; Larry Borish
Journal:  Immunol Allergy Clin North Am       Date:  2019-05-15       Impact factor: 3.479

4.  CDHR3 Asthma-Risk Genotype Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections.

Authors:  Sarmila Basnet; Yury A Bochkov; Rebecca A Brockman-Schneider; Ine Kuipers; Scott W Aesif; Daniel J Jackson; Robert F Lemanske; Carol Ober; Ann C Palmenberg; James E Gern
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

Review 5.  Impact of Rhinovirus Infections in Children.

Authors:  Silvia Vandini; Carlotta Biagi; Maximilian Fischer; Marcello Lanari
Journal:  Viruses       Date:  2019-06-05       Impact factor: 5.048

Review 6.  Viral Induced Effects on a Vulnerable Epithelium; Lessons Learned From Paediatric Asthma and Eosinophilic Oesophagitis.

Authors:  Rebecca L Watkinson; Kevin Looi; Ingrid A Laing; Antonella Cianferoni; Anthony Kicic
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.